Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 99, Issue 1, Pages 36-37Publisher
WILEY-BLACKWELL
DOI: 10.1002/cpt.161
Keywords
-
Categories
Funding
- NHLBI NIH HHS [U01 HL105198, U01 HL0105198] Funding Source: Medline
- NIGMS NIH HHS [UO1 GM92666, R24 GM061374, R24 GM115264, R24 GM61374, U01 GM092666] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105198] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM115264, R24GM061374, U01GM092666] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB ().
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available